Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
NCT02396966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152
Last updated 2018-12-21
Summary
The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-12-31
- Primary Completion
- 2018-05-31
- Completion
- 2018-05-31
Countries
- Poland
Study Locations
More Related Trials
-
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363 ·Status: COMPLETED ·Phase: PHASE4
-
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
NCT01471405 ·Status: COMPLETED
-
Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly
NCT04003519 ·Status: WITHDRAWN
-
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
NCT02396953 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
NCT00234572 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
NCT00444873 ·Status: COMPLETED ·Phase: PHASE3
-
Study in Polish Acromegalic Patients Treated With Somatuline Autogel
NCT01333384 ·Status: COMPLETED
-
Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT02807233 ·Status: COMPLETED
-
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
NCT00517491 ·Status: WITHDRAWN ·Phase: PHASE2
-
Somatuline Autogel: Acromegaly Self/Partner Injection Study
NCT00149188 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
NCT00447499 ·Status: COMPLETED ·Phase: PHASE3
-
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00627796 ·Status: COMPLETED ·Phase: PHASE4
-
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT00383708 ·Status: COMPLETED ·Phase: PHASE3
-
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
NCT02698384 ·Status: TERMINATED
-
Acromegaly Treatment Quality of Life Study
NCT01732406 ·Status: COMPLETED
-
Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
NCT00145405 ·Status: COMPLETED ·Phase: PHASE4
-
Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas
NCT00993356 ·Status: UNKNOWN ·Phase: PHASE2
-
Non Interventional Post Marketing Programme in Acromegaly
NCT00747500 ·Status: COMPLETED
-
Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
NCT05431803 ·Status: COMPLETED
-
Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
NCT06607666 ·Status: COMPLETED
-
Somatuline Predictive Factors in Acromegaly and NET
NCT01840449 ·Status: COMPLETED
-
Predictive Factors Study
NCT02020499 ·Status: TERMINATED
-
Lanreotide Levels in Acromegaly
NCT00916916 ·Status: UNKNOWN
-
Acromegaly Combination Treatment Study
NCT01538966 ·Status: TERMINATED ·Phase: NA
-
Treatment Patterns and Treatment Outcomes for Acromegaly
NCT03043586 ·Status: COMPLETED